(Q45381659)

English

Probabilistic cost-effectiveness analysis of the long-term effect of universal hepatitis B vaccination: an experience from Taiwan with high hepatitis B virus infection and Hepatitis B e Antigen positive prevalence

scientific article published on 5 September 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Probabilistic cost-effectiveness analysis of the long-term effect of universal hepatitis B vaccination: an experience from Taiwan with high hepatitis B virus infection and Hepatitis B e Antigen positive prevalence (English)

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Hepatitis B virus

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

2

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

author name string

Hui-Fang Hung

1

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

language of work or name

0 references

publication date

5 September 2009

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

27

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

48

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

6770-6776

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Global control of hepatitis B virus infection.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.082

7 January 2021

Epidemiological characteristics and risk factors of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.082

7 January 2021

Prevention of hepatitis B virus transmission by immunization. An economic analysis of current recommendations

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.082

7 January 2021

Seroepidemiology of hepatitis B virus infection in children: Ten years of mass vaccination in Taiwan

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.082

7 January 2021

Pediatric fulminant hepatic failure in endemic areas of hepatitis B infection: 15 years after universal hepatitis B vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.082

7 January 2021

Cost effectiveness of hepatitis B vaccination strategies in Ireland: an economic evaluation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.082

7 January 2021

Cost-effectiveness of screening and vaccinating Asian and Pacific Islander adults for hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.082

7 January 2021

Vaccination against hepatitis B virus in Spain: a cost-effectiveness analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.082

7 January 2021

Immune status in preschool children born after mass hepatitis B vaccination program in Taiwan

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.082

7 January 2021

Long-term immunogenicity and efficacy of universal hepatitis B virus vaccination in Taiwan.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.082

7 January 2021

Hepatitis B virus infection in children and adolescents in a hyperendemic area: 15 years after mass hepatitis B vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.082

7 January 2021

Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.082

7 January 2021

Epidemiological patterns of hepatitis B virus (HBV) in highly endemic areas

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.082

7 January 2021

Ten-year neonatal hepatitis B vaccination program, The Netherlands, 1982-1992: protective efficacy and long-term immunogenicity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.082

7 January 2021

Prevention of hepatitis B virus carrier state in infants according to maternal serum levels of HBV DNA.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.082

7 January 2021

Prevention of maternal-infant hepatitis B virus transmission by immunization: the role of serum hepatitis B virus DNA.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.082

7 January 2021

The influence of age on the development of the hepatitis B carrier state

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.082

7 January 2021

A mathematical model to estimate global hepatitis B disease burden and vaccination impact.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.082

7 January 2021

Additive effect modification of hepatitis B surface antigen and e antigen on the development of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.082

7 January 2021

Assessment of cost-effectiveness of universal hepatitis B immunization in a low-income country with intermediate endemicity using a Markov model.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.082

7 January 2021

The cost-effectiveness of introducing hepatitis B vaccine into infant immunization services in Mozambique.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.082

7 January 2021

Costs and benefits of polio eradication: a long-run global perspective

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.082

7 January 2021

Baseline seroepidemiology of hepatitis B virus infection in children in Taipei, 1984: a study just before mass hepatitis B vaccination program in Taiwan.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.082

7 January 2021

Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.082

7 January 2021

Evolution of acute hepatitis B in homosexual men to chronic hepatitis B. Prospective study of placebo recipients in a hepatitis B vaccine trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.082

7 January 2021

Natural history of acute hepatitis B surface antigen-positive hepatitis in Greek adults

2 references

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.082

7 January 2021

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.082

7 January 2021

based on heuristic

inferred from DOI database lookup

Severe viral hepatitis type B in infancy;

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.082

7 January 2021

[Seven-year follow-up studies on asymptomatic HBs Ag carriers]

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.082

7 January 2021

Prospective study of hepatocellular carcinoma and liver cirrhosis in asymptomatic chronic hepatitis B virus carriers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.082

7 January 2021

Serologic and clinical outcomes of 1536 Alaska Natives chronically infected with hepatitis B virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.082

7 January 2021

The long-term serological course of asymptomatic hepatitis B virus carriers and the development of primary hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.082

7 January 2021

Mortality of hepatitis B surface antigen-positive blood donors in England and Wales

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.082

7 January 2021

The development of cirrhosis in patients with chronic type B hepatitis: A prospective study

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.082

7 January 2021

Natural history and prognostic factors for chronic hepatitis type B

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.082

7 January 2021

Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation of 2215 patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.082

7 January 2021

Long-term follow-up of chronic active hepatitis of moderate severity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.082

7 January 2021

The Natural Course of Hepatitis B Surface Antigen—Positive Chronic Active Hepatitis in Taiwan

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.082

7 January 2021

Survival and prognostic indicators in compensated and decompensated cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.082

7 January 2021

Natural history and prognosis of hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.082

7 January 2021

Health care costs of multiple sclerosis in Austria. Cross-sectional study including consideration of quality of life

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.082

7 January 2021

A reappraisal of hepatitis B virus vaccination strategies using cost-effectiveness analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.082

7 January 2021

Clinical and economic impact of a combination Haemophilus influenzae and Hepatitis B vaccine: estimating cost-effectiveness using decision analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.082

7 January 2021

Cost-benefit analysis of a nationwide neonatal inoculation programme against hepatitis B in an area of intermediate endemicity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.082

7 January 2021

Immunization programme against hepatitis B virus infection in Italy: cost-effectiveness

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.082

7 January 2021

Viral hepatitis: clinical aspects

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.082

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2009.08.082

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45381659&oldid=2076271275"